New Study Shows Rapid EGFR testing with Idylla!
Products are for professional/laboratory use only.
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
24Mar
News
02Feb
Biocartis Launches Liquid Biopsy Idylla™ ctEGFR Mutation Assay (RUO)
Products are for professional/laboratory use only.
Biocartis is pleased to announce the launch of the Idylla™ ctEGFR Mutation Assay (RUO1). This assay is the liquid biopsy version of the solid biopsy Idylla™ EGFR Mutation Test (CE-IVD).
02Feb
Biocartis announces CE-IVD marking of its Idylla™ MSI Test
Products are for professional/laboratory use only.
Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE[1] colorectal cancer tumor tissue. This CE-IVD launch is a key addition to Biocartis’ colorectal cancer (CRC) Idylla™ test menu as MSI detection is currently recommended for all patients with CRC[2].
02Feb
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX Genomic Prostate Score® Test.
Products are for professional/laboratory use only.
On the 3rd of December, Genomic Health, Inc and Biocartis Group NV announced that they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version* of the Oncotype DX Genomic Prostate Score® (GPS™) Test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.
03Feb
Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
Products are for professional/laboratory use only.
Press Release: Mechelen, Belgium, 27 June 2018
03Feb
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
Products are for professional/laboratory use only.
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
03Feb
Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests
Products are for professional/laboratory use only.
A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).
03Feb
Biocartis ctKRAS Mutation Assay (Research Use Only, RUO)
Products are for professional/laboratory use only.
The Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.
03Feb
Idylla EGFR Mutation Test (CE-IVD)
Products are for professional/laboratory use only.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
